231 related articles for article (PubMed ID: 36720973)
1. KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition.
Boila LD; Ghosh S; Bandyopadhyay SK; Jin L; Murison A; Zeng AGX; Shaikh W; Bhowmik S; Muddineni SSNA; Biswas M; Sinha S; Chatterjee SS; Mbong N; Gan OI; Bose A; Chakraborty S; Arruda A; Kennedy JA; Mitchell A; Lechman ER; Banerjee D; Milyavsky M; Minden MD; Dick JE; Sengupta A
Leukemia; 2023 Apr; 37(4):751-764. PubMed ID: 36720973
[TBL] [Abstract][Full Text] [Related]
2. MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Biswas M; Chatterjee SS; Boila LD; Chakraborty S; Banerjee D; Sengupta A
FASEB J; 2019 Apr; 33(4):5268-5286. PubMed ID: 30668141
[TBL] [Abstract][Full Text] [Related]
3. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
4. Loss of KDM6A confers drug resistance in acute myeloid leukemia.
Stief SM; Hanneforth AL; Weser S; Mattes R; Carlet M; Liu WH; Bartoschek MD; Domínguez Moreno H; Oettle M; Kempf J; Vick B; Ksienzyk B; Tizazu B; Rothenberg-Thurley M; Quentmeier H; Hiddemann W; Vosberg S; Greif PA; Metzeler KH; Schotta G; Bultmann S; Jeremias I; Leonhardt H; Spiekermann K
Leukemia; 2020 Jan; 34(1):50-62. PubMed ID: 31201358
[TBL] [Abstract][Full Text] [Related]
5. Lysine Demethylase KDM6A in Differentiation, Development, and Cancer.
Tran N; Broun A; Ge K
Mol Cell Biol; 2020 Sep; 40(20):. PubMed ID: 32817139
[TBL] [Abstract][Full Text] [Related]
6. KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia.
Boila LD; Chatterjee SS; Banerjee D; Sengupta A
Exp Hematol; 2018 Feb; 58():44-51.e7. PubMed ID: 29111428
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
8. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
9. Lysine Demethylase 6B Regulates Prostate Cancer Cell Proliferation by Controlling c-MYC Expression.
Yıldırım-Buharalıoğlu G
Mol Pharmacol; 2022 Feb; 101(2):106-119. PubMed ID: 34862309
[TBL] [Abstract][Full Text] [Related]
10. Catalysis by KDM6 Histone Demethylases - A Synergy between the Non-Heme Iron(II) Center, Second Coordination Sphere, and Long-Range Interactions.
Rifayee SBJS; Chaturvedi SS; Warner C; Wildey J; White W; Thompson M; Schofield CJ; Christov CZ
Chemistry; 2023 Sep; 29(51):e202301305. PubMed ID: 37258457
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Wang L; Cai W; Zhang W; Chen X; Dong W; Tang D; Zhang Y; Ji C; Zhang M
Oncotarget; 2015 Sep; 6(29):27490-504. PubMed ID: 26314963
[TBL] [Abstract][Full Text] [Related]
12. KDM6 demethylase independent loss of histone H3 lysine 27 trimethylation during early embryonic development.
Shpargel KB; Starmer J; Yee D; Pohlers M; Magnuson T
PLoS Genet; 2014 Aug; 10(8):e1004507. PubMed ID: 25101834
[TBL] [Abstract][Full Text] [Related]
13. Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax.
Gaur T; Poddutoori R; Khare L; Bagal B; Rashmi S; Patkar N; Tembhare P; Pg S; Shetty D; Dutt A; Zhang Q; Konopleva M; Platzbeckar U; Gupta S; Samajdar S; Ramchandra M; Khattry N; Hasan SK
J Exp Clin Cancer Res; 2023 Jul; 42(1):186. PubMed ID: 37507802
[TBL] [Abstract][Full Text] [Related]
14. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
[TBL] [Abstract][Full Text] [Related]
15. SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade.
Romero OA; Vilarrubi A; Alburquerque-Bejar JJ; Gomez A; Andrades A; Trastulli D; Pros E; Setien F; Verdura S; Farré L; Martín-Tejera JF; Llabata P; Oaknin A; Saigi M; Piulats JM; Matias-Guiu X; Medina PP; Vidal A; Villanueva A; Sanchez-Cespedes M
Nat Commun; 2021 Jul; 12(1):4319. PubMed ID: 34262032
[TBL] [Abstract][Full Text] [Related]
16. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
[TBL] [Abstract][Full Text] [Related]
17. Vitamin C-dependent lysine demethylase 6 (KDM6)-mediated demethylation promotes a chromatin state that supports the endothelial-to-hematopoietic transition.
Zhang T; Huang K; Zhu Y; Wang T; Shan Y; Long B; Li Y; Chen Q; Wang P; Zhao S; Li D; Wu C; Kang B; Gu J; Mai Y; Wang Q; Li J; Zhang Y; Liang Z; Guo L; Wu F; Su S; Wang J; Gao M; Zhong X; Liao B; Chen J; Zhang X; Shu X; Pei D; Nie J; Pan G
J Biol Chem; 2019 Sep; 294(37):13657-13670. PubMed ID: 31341023
[TBL] [Abstract][Full Text] [Related]
18.
Molenaar RJ; Radivoyevitch T; Nagata Y; Khurshed M; Przychodzen B; Makishima H; Xu M; Bleeker FE; Wilmink JW; Carraway HE; Mukherjee S; Sekeres MA; van Noorden CJF; Maciejewski JP
Clin Cancer Res; 2018 Apr; 24(7):1705-1715. PubMed ID: 29339439
[No Abstract] [Full Text] [Related]
19. Therapeutic Potentials of Inhibition of Jumonji C Domain-containing Demethylases in Acute Myeloid Leukemia.
Koca D; Hastar N; Engür S; Kiraz Y; Ulu GT; Çekdemir D; Baran Y
Turk J Haematol; 2020 Feb; 37(1):5-12. PubMed ID: 31833715
[TBL] [Abstract][Full Text] [Related]
20. High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.
Pan J; Wang Y; Huang S; Mao S; Ling Q; Li C; Li F; Yu M; Huang X; Huang J; Lv Y; Li X; Ye W; Wang H; Wang J; Jin J
J Mol Med (Berl); 2024 Mar; 102(3):415-433. PubMed ID: 38340163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
